Clinical trial · Observational
Protocol to Distinguish Tumor Recurrence From Treatment-Related Necrosis in Patients With High Grade Gliomas
DMS-0901: Multimodal Magnetic Resonance Protocol to Distinguish Tumor Recurrence From Treatment-Related Necrosis in Patients With High Grade Gliomas
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Brain imaging tests are routinely used to detect the presence of a brain tumor or to evaluate the response to treatment. Sometimes the images obtained are not specific and the only way to establish a diagnosis is by obtaining a tissue sample. The hypotheses of the study is to determine if multimodal MR technique will provide tissue signatures that differentiate between tumor progression and treatment related necrosis in high grade glioma patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent High Grade Gliomas | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 3T MRI | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Research MRI
- description
- High Grade Glioma patients who show progression based on MRI
- interventionNames
- Device: 3T MRI
Primary outcomes (1)
- measure
- To prospectively acquire multiparameter MR variables at 1.5T and 3T MRI from treated high grade glioma patients to assign tissue signatures for tumor recurrence and radiation necrosis as established by pathologic examination.
- timeFrame
- 24 months
Secondary outcomes (1)
- measure
- To compare the predictive values of the multiparameter MR tissue signatures acquired at 1.5T and 3T
- timeFrame
- 24 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven high grae glioma with central pathology review at DHMC * Age 18 equal to or greater than 18 years * Karnofsky performance greater or equal to 60% * Patients must have received radiation therapy and chemotherapy but should not have received any anti-angiogenesis therapy. Exclusion Criteria: * Any patient who requires urgent surgical resection of MRI abnormality would not be eligible * Pregnant women are not eligible
References
Publications (0)
Data not yet available